Dynavax Technologies Corp. (NASDAQ:DVAX) shares were up 5% on Wednesday . The stock traded as high as $15.59 and last traded at $15.52, with a volume of 271,936 shares changing hands. The stock had previously closed at $14.78.

Several research analysts have recently commented on the stock. Zacks Investment Research cut shares of Dynavax Technologies Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, April 19th. JPMorgan Chase & Co. cut shares of Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $29.00 to $22.00 in a report on Wednesday, April 27th. Royal Bank Of Canada cut shares of Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $48.00 to $17.00 in a report on Wednesday, April 27th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $60.00 target price on shares of Dynavax Technologies Corp. in a report on Thursday, April 28th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $32.20.

The company’s market cap is $598.21 million. The firm’s 50 day moving average price is $14.76 and its 200 day moving average price is $17.90.

Dynavax Technologies Corp. (NASDAQ:DVAX) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.07. The business had revenue of $942 million for the quarter, compared to analysts’ expectations of $627 million. Equities research analysts expect that Dynavax Technologies Corp. will post ($2.90) EPS for the current fiscal year.

In other Dynavax Technologies Corp. news, CEO Eddie Gray purchased 2,750 shares of the company’s stock in a transaction that occurred on Friday, May 20th. The shares were bought at an average cost of $15.57 per share, for a total transaction of $42,817.50. Following the purchase, the chief executive officer now owns 5,050 shares of the company’s stock, valued at approximately $78,628.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

A number of hedge funds have recently bought and sold shares of the company. Trexquant Investment LP raised its stake in Dynavax Technologies Corp. by 14.5% in the fourth quarter. Trexquant Investment LP now owns 70,200 shares of the biopharmaceutical company’s stock worth $1,696,000 after buying an additional 8,911 shares during the period. California State Teachers Retirement System raised its stake in Dynavax Technologies Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,895 shares of the biopharmaceutical company’s stock worth $1,640,000 after buying an additional 1,177 shares during the period. Finally, Swiss National Bank raised its stake in Dynavax Technologies Corp. by 5.7% in the fourth quarter. Swiss National Bank now owns 48,528 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 2,600 shares during the period.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.